Your search for psilocybin returned 12 results

No difference seen in change in depression scores at six weeks for psilocybin plus placebo versus psilocybin plus escitalopram

Reductions in anxiety, depression in cancer-related psychiatric distress sustained at 3.2 and 4.5 years.

The FDA has granted Breakthrough Therapy designation to psilocybin for the treatment of major depressive disorder.

The designation was granted to COMPASS Pathways, a life sciences company investigating psilocybin in a Phase 2b trial involving 216 patients at multiple sites across Europe and North America.

Currently, psilocybin, a serotonin receptor agonist, is classified as a Schedule I agent as it has not been approved by the Food and Drug Administration (FDA) for any therapeutic use.

The trial will be a Phase 2b dose-ranging study (N=216) with patients from 12-15 research centers across Europe and North America.

A single moderate-dose of psilocybin (a hallucinogenic compound contained in psychedelic mushrooms) was found to produce enduring anxiolytic and antidepressant effects in distressed cancer patients with life-threatening diagnoses.

According to a study in The American Journal of Drug and Alcohol Abuse, psilocybin showed promise in promoting long-term smoking abstinence in the context of a structured treatment program.

Results from a recent study published in The Lancet Psychiatry demonstrates preliminary support for the safety and efficacy of the hallucinogenic compound, psilocybin, for the management of treatment-resistant depression.

A single dose of psilocybin can alleviate negative moods in patients with life-threatening cancer, a new study has found.